Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial

Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial

Current pharmacologic treatments for pediatric anxiety disorders (e.g., selective serotonin reuptake inhibitors (SSRIs)) frequently use “one size fits all” dosing strategies based on average responses in clinical trials. However, for some SSRIs, including escitalopram, variation in CYP2C19 activity...

Full description

Bibliographic Details
Main Authors: Jeffrey R. Strawn, Ethan A. Poweleit, Jeffrey A. Mills, Heidi K. Schroeder, Zoe A. Neptune, Ashley M. Specht, Jenni E. Farrow, Xue Zhang, Lisa J. Martin, Laura B. Ramsey
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Journal of Personalized Medicine
Subjects:
selective serotonin reuptake inhibitor (SSRI)
anxiety disorders
generalized anxiety disorder (GAD)
pharmacogenetic
CYP2C19
pharmacokinetic
Online Access:https://www.mdpi.com/2075-4426/11/11/1188

Internet

https://www.mdpi.com/2075-4426/11/11/1188

Similar Items